- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity | 92 | GlobeNewswire (Europe) | MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 20.02. | Pasithea Therapeutics Corp. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.01. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | 176 | GlobeNewswire (Europe) | MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral... ► Artikel lesen | |
| 15.12.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright | 2 | Investing.com | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | 1 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up | 4 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | Pasithea Therapeutics Corp. - S-1/A, General form for registration of securities | 14 | SEC Filings | ||
| 25.11.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ALS Association awards $1 million to study Pasithea's PAS-004 in ALS | 2 | Investing.com | ||
| 24.11.25 | Pasithea reports positive safety data from PAS-004 cancer trial | 7 | Investing.com | ||
| 21.11.25 | Pasithea reports positive PK data for PAS-004 tablet formulation | 1 | Investing.com | ||
| 21.11.25 | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 309 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| 20.11.25 | Pasithea meldet positive Zwischendaten für MEK-Inhibitor in Krebsstudie | 5 | Investing.com Deutsch | ||
| 20.11.25 | Pasithea reports positive interim data for MEK inhibitor in cancer trial | 1 | Investing.com | ||
| 20.11.25 | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 236 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| 18.11.25 | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | - | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,512 | +0,93 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| ABIVAX | 103,70 | -3,26 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,655 | +6,83 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| GENPREX | 1,245 | +5,96 % | Genprex, Inc.: Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer | Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq®
AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex... ► Artikel lesen | |
| REZOLUTE | 3,160 | +1,28 % | Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update | REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 66,25 | 0,00 % | Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 6,620 | -0,30 % | Brookline Capital cuts Unicycive stock price target on share count | ||
| DAMORA THERAPEUTICS | 26,380 | 0,00 % | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| FIBROBIOLOGICS | 1,375 | +3,77 % | FibroBiologics presents preclinical data on thymic organoids | ||
| QIAGEN | 35,350 | +0,91 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 16,310 | 0,00 % | What's Driving Erasca (ERAS)'s Nearly 355% YTD Return | ||
| BIONTECH | 82,30 | +1,04 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| ALLOGENE THERAPEUTICS | 3,050 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,75 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen |
Das Unternehmen PASITHEA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,746 Euro und damit +6,59 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.